Navigation Links
Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
Date:1/28/2013

CLEVELAND, Jan. 28, 2013 /PRNewswire-USNewswire/ -- Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease announced today that Paul Resnick , M.D., M.B.A., has joined the company as Vice President of Business Development.  Dr. Resnick brings more than 25 years of healthcare and business development experience to the role.  In this position, Dr. Resnick's efforts will be to drive business development efforts while supporting the company's broader corporate strategic vision.

(Logo: http://photos.prnewswire.com/prnh/20120820/DC59281LOGO )

Juventas' technology platform is based on developing factors that activate or enhance natural stem-cell based repair pathways.  The company is currently enrolling Phase II clinical trials in heart failure (HF) and critical limb ischemia (CLI) for lead product JVS-100.  JVS-100 encodes Stromal cell-Derived Factor 1 (SDF-1), which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death, and restoration of blood flow.  

Dr. Resnick's professional experience includes product and business development from early-stage private companies to top five pharmaceutical companies.  Most recently, Dr. Resnick led business development for Intellikine, culminating in its acquisition last year by Takeda Pharmaceuticals for $190 million upfront and up to $120 million in potential clinical milestones. He also played a key role in the Rinat Neurosciences acquisition by Pfizer in 2007 for $500 million in cash. 

"We are delighted to welcome Paul to Juventas' senior management team," commented Rahul Aras, President and Chief Executive Officer.  "Given the development stage and clinical potential for JVS-100, we believe having someone with Paul's experience focused on strategic opportunities will allow us to best recognize the long-term value of this platform."

"I'm thrilled to join the Juventas team," remarked Dr. Resnick.  "Juventas is pursuing a unique therapeutic strategy in the exciting field of regenerative medicine.  Through activation of a patient's own stem-cell repair processes, JVS-100 delivers regenerative benefits without the cost and complexities typically associated with cell-based therapeutics.  I look forward to applying my industry perspective and leveraging my contacts to help Juventas transition toward commercialization."

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, OH, is a privately held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials for treatment of heart failure and critical limb ischemia.  Investors include Triathlon Medical Ventures, New Science Ventures, Takeda Ventures, Venture Investors, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, Glengary, The Global Cardiovascular Innovation Center, Tri-State Growth Fund, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received non-dilutive grant support through the Ohio Third Frontier-funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.


'/>"/>
SOURCE Juventas Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Juventas Therapeutics Raises $22.2 Million Series B Financing
2. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
3. Shield Therapeutics Selects OpenClinica Enterprise
4. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
5. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
6. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
7. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
8. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
9. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
10. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
11. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/9/2016)... 2016  Perkotek an innovation leader in attendance control systems is proud to announce ... for employers to make sure the right employees are actually signing in, and to ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):